Absci announced expectations for interim proof-of-concept data for its ABS-201 candidate in the second half of 2026. The biotechnology firm also provided updated financial guidance, projecting its cash runway to extend into the second half of 2028.
Absci Projects ABS-201 Data in H2 2026, Extends Cash Runway to H2 2028
BiotechnologyPharmaceuticalsCash RunwayClinical TrialsABSI

